Hermetica Superfood Encyclopedia
The Short Answer
Agaricus blazei Murrill delivers immunomodulatory beta-glucan polysaccharides and ergosterol that stimulate innate and adaptive immunity by upregulating TNF-α, IL-6, and CD4⁺/CD8⁺ T-cell ratios while inhibiting tumor proliferation through direct cytotoxic mechanisms. In murine models, isolated ergosterol suppressed tumor growth with a dose-dependent response ranging from 20.6% suppression at 10 mg/kg to 84.7% suppression at 200 mg/kg intraperitoneally, representing one of the strongest preclinical antitumor signals documented for a culinary-medicinal mushroom.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordAgaricus blazei benefits
Agaricus blazei — botanical close-up
Health Benefits
**Immune Modulation**
Beta-glucan polysaccharides (AbMP) significantly increase TNF-α and IL-6 secretion and expand CD4⁺/CD8⁺ T-cell populations at 150–200 mg/kg/day in animal models, supporting coordinated innate and adaptive immune responses.
**Antitumor Activity**
Ergosterol isolated from AbM suppresses tumor growth in murine sarcoma models with suppression ratios scaling from 20.6% at 10 mg/kg to 84.7% at 200 mg/kg intraperitoneally, likely through apoptosis induction and anti-angiogenic effects.
**Anti-inflammatory Regulation**
At higher concentrations (250–1000 μg/mL), AbMP polysaccharides paradoxically reduce TNF-α and nitric oxide (NO) secretion in a concentration-dependent manner, suggesting a biphasic immunomodulatory profile useful in managing inflammatory excess.
**Antifungal Defense**
Isolated linoleic acid and glycerol monolinoleate from AbM inhibit dermatophyte species including Trichophyton at >50% inhibitory rates at 25 μg/mL, with glycerol monolinoleate identified structurally by a characteristic carbonyl resonance at δC 174.35 ppm via NMR.
**Antidiabetic Potential**
Ethanol extracts of AbM inhibit α-glucosidase activity by 64.86–73.45% at 8 mg/mL in vitro, a mechanism analogous to pharmaceutical alpha-glucosidase inhibitors that delay postprandial glucose absorption.
**Antioxidant Activity**: Phenolic compounds including gallic acid (4
50 ± 0.10 μg/mg extract) and syringic acid (5.70 ± 0.10 μg/mg extract) contribute to free-radical scavenging capacity, supporting cellular protection against oxidative stress.
**Nutritional Immune Support**
AbM provides ergosterol (73–90 mg/100g dry powder), a provitamin D2 precursor, alongside B vitamins (B1: 381–1151 μg/100g dry powder) and linoleic acid, offering a multi-nutrient matrix that complements its direct immunopharmacological effects.
Origin & History
Natural habitat
Agaricus blazei Murrill is a basidiomycete mushroom native to the Atlantic Forest region of southeastern Brazil, particularly around the municipality of Piedade in São Paulo state, where it grows in humus-rich soils during warm, humid seasons. It was introduced to Japan in the 1960s by Japanese-Brazilian researchers and rapidly adopted as a cultivated medicinal and edible fungus, thriving in controlled substrate environments of rice straw, sugarcane bagasse, and cottonseed hulls. Commercial cultivation is now widespread across Japan, China, Brazil, and South Korea, with fruiting bodies harvested at the primordium stage to maximize bioactive polysaccharide content.
“Agaricus blazei has been consumed for generations by the rural community of Piedade, Brazil, where local inhabitants attributed its regular dietary use to notably low rates of adult-onset diseases including cancer and diabetes, a claim that attracted the attention of Japanese researchers Takatoshi Furumoto and Inosuke Fukumoto in the 1960s who subsequently introduced samples to Japan for scientific investigation. In Japan, the mushroom became commercially branded as 'Himematsutake' (姫松茸, meaning 'princess matsutake') or 'Kawariharatake,' and was cultivated extensively in Shizuoka and Kochi prefectures, becoming one of the highest-value medicinal mushrooms in Japanese natural health markets by the 1990s. Traditional Brazilian use involved direct consumption of fresh or sun-dried fruiting bodies as a food staple rather than a medicine, while Japanese traditional preparation evolved toward hot-water decoctions and commercial extract capsules positioned explicitly for immune and antitumor support. The mushroom features prominently in integrative oncology discussions in East Asia, where it is often used as an adjunct to chemotherapy to support immune function, though this practice precedes robust clinical validation.”Traditional Medicine
Scientific Research
The current evidence base for Agaricus blazei Murrill consists predominantly of in vitro cell culture experiments and in vivo murine studies, with a limited number of small, non-randomized human observational trials primarily conducted in Japanese oncology settings evaluating quality-of-life and NK-cell activity endpoints; no large-scale, double-blind randomized controlled trials with clearly defined primary efficacy endpoints have been published as of the most recent literature reviews. Murine tumor suppression studies using intraperitoneally administered ergosterol demonstrate robust dose-response relationships (20.6–84.7% suppression), but intraperitoneal dosing does not reflect oral bioavailability in humans, substantially limiting translational relevance. Immunological parameters such as cytokine induction (TNF-α, IL-6) and T-cell subset ratios have been replicated across multiple independent animal studies, lending moderate preclinical credibility to the immunomodulatory claim, though effect sizes in human immune assays remain poorly characterized. The antifungal and alpha-glucosidase inhibition data are exclusively in vitro and require pharmacokinetic confirmation before clinical conclusions can be drawn.
Preparation & Dosage
Traditional preparation
**Dried Whole Powder (most traditional form)**
1–3 g per day in humans, derived from analogizing Japanese traditional consumption patterns; no standardized clinical dose established
Typically .
**Hot-Water Extract (polysaccharide-enriched)**
500–1500 mg/day have been used in Japanese observational cancer-support studies
Commonly standardized to 30–40% beta-glucan content; doses of .
**Ethanol/Ethyl Acetate Extract**
8 mg/mL in vitro — direct human dose equivalence not established
Used experimentally for phenolic and antifungal compound isolation; alpha-glucosidase inhibition demonstrated at .
**Animal Reference Doses (not directly translatable)**
150–200 mg/kg/day orally for immunostimulation; ergosterol 10–200 mg/kg intraperitoneally for antitumor effects in mice
AbMP polysaccharide .
**Freeze-Dried Powder**
Retains uronic acid content (~28.19% in freeze-dried material); preferred for preserving water-soluble polysaccharide fractions.
**Tea/Decoction (traditional Brazilian preparation)**
Dried fruiting bodies simmered in water; duration and concentration vary by tradition, no standardized protocol exists.
**Timing**
Typically taken with or before meals when used for glycemic or digestive support; immunological applications have no established optimal timing in human data.
Nutritional Profile
Agaricus blazei fruiting bodies provide glucose as the dominant carbohydrate (83.59% of dry powder; 403–852 mg/100g fresh weight), with smaller quantities of mannose (0.59% dry powder; 49–81 mg/100g fresh weight) and galactose contributing to its polysaccharide matrix. Lipid constituents include ergosterol at 73–90 mg/100g dry powder — a provitamin D2 precursor activated by UV exposure — and linoleic acid (omega-6), an essential fatty acid with demonstrated antifungal properties at physiological concentrations. Vitamin B1 (thiamine) is present at 381–1151 μg/100g dry powder, with vitamins C and D also reported; phenolic content is relatively modest at 0.77 ± 0.12 mg/100g dry powder, with gallic acid (4.50 ± 0.10 μg/mg extract) and syringic acid (5.70 ± 0.10 μg/mg extract) as identified antioxidant phenolics. Trehalose (5.74 ± 0.70 mg/100g dry powder) serves as a structural disaccharide and potential osmoprotectant, while uronic acid content in freeze-dried material (28.19 ± 1.39%) reflects the contribution of acidic polysaccharides to the bioactive carbohydrate fraction; bioavailability of beta-glucans is enhanced by hot-water extraction compared to raw powder consumption.
How It Works
Mechanism of Action
Agaricus blazei polysaccharides (AbMP), primarily composed of β-(1→3) and β-(1→6)-glucans with mannose and galactose branches, bind pattern recognition receptors including Dectin-1 and TLR-2/4 on macrophages and dendritic cells, triggering NF-κB-mediated transcription of pro-inflammatory cytokines TNF-α and IL-6 at immunostimulatory doses (150–200 mg/kg), while high-dose exposure (250–1000 μg/mL) shifts the response toward inhibition of TNF-α and nitric oxide synthase, indicating receptor saturation or regulatory T-cell induction. Ergosterol exerts antitumor effects potentially via induction of caspase-dependent apoptotic cascades, suppression of topoisomerase activity, and inhibition of tumor-associated angiogenesis, as inferred from its dose-response suppression ratios in murine Sarcoma 180 models. Linoleic acid and glycerol monolinoleate disrupt fungal cell membrane integrity in dermatophytes, likely by intercalating into lipid bilayers and compromising membrane fluidity, while gallic and syringic acids chelate transition metals and quench reactive oxygen species via electron donation. Alpha-glucosidase inhibition by AbM ethanol extracts occurs through competitive or mixed-mode binding at the enzyme's active site, slowing intestinal glucose release and attenuating postprandial glycemic excursions.
Clinical Evidence
Human clinical investigation of Agaricus blazei remains at an early stage; available reports include small Japanese studies in cancer patients receiving AbM extract alongside conventional chemotherapy, where outcomes assessed included NK cell activity, leukocyte counts, and self-reported quality-of-life scores, with some patients showing preserved or enhanced NK cell function during treatment. One frequently cited open-label Japanese study in cervical, ovarian, and endometrial cancer patients found that AbM extract supplementation was associated with improvements in NK cell activity compared to non-supplemented controls, but the absence of randomization, blinding, and standardized extract dosing substantially weakens these findings. No phase II or III randomized clinical trials evaluating AbM for tumor response rates, survival endpoints, glycemic control, or infection outcomes in humans have been published, making it premature to assign clinical therapeutic recommendations. Confidence in the current clinical evidence is low; the preclinical mechanistic data are biologically plausible but human efficacy and optimal dosing remain unestablished.
Safety & Interactions
Formal toxicological studies and structured adverse event reporting for Agaricus blazei in humans are sparse in the published literature; available safety data derive primarily from traditional consumption histories in Brazil and Japan, where it has been consumed without widely reported serious adverse effects, but systematic pharmacovigilance data are absent. Theoretical drug interactions warrant caution with immunosuppressive medications (e.g., cyclosporine, tacrolimus, corticosteroids) given AbM's documented capacity to upregulate TNF-α, IL-6, and T-cell activity, which could oppose immunosuppressive therapy in transplant or autoimmune disease contexts. The alpha-glucosidase inhibitory activity demonstrated in vitro raises a hypothetical additive hypoglycemic risk when combined with acarbose, metformin, or insulin, necessitating blood glucose monitoring if used concurrently by diabetic patients. No maximum safe human dose has been formally established; pregnancy and lactation use should be avoided due to the absence of reproductive toxicity data, and individuals with mushroom allergies or known Agaricaceae hypersensitivity should not use AbM products.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Agaricus blazei MurrillHimematsutakeKawariharatakeRoyal Sun AgaricusCogumelo do SolCogumelo de DeusAbMAgaricus subrufescens
Frequently Asked Questions
What are the main health benefits of Agaricus blazei mushroom?
Agaricus blazei provides immunomodulatory beta-glucan polysaccharides that upregulate TNF-α, IL-6, and CD4⁺/CD8⁺ T-cell ratios, supporting immune surveillance and response. Its isolated ergosterol compound demonstrated antitumor suppression ratios of 20.6–84.7% in murine models depending on dose, while ethanol extracts inhibit alpha-glucosidase by 64.86–73.45% at 8 mg/mL, suggesting potential glycemic support. Additional benefits include antifungal activity from linoleic acid and antioxidant effects from gallic and syringic acid phenolics.
What is the recommended dosage of Agaricus blazei supplement?
No universally standardized human clinical dose has been established for Agaricus blazei due to limited large-scale clinical trials. Japanese observational studies and traditional use patterns have employed hot-water polysaccharide extracts standardized to 30–40% beta-glucans at approximately 500–1500 mg per day, while dried whole mushroom powder is often used at 1–3 g per day. Animal research doses of 150–200 mg/kg/day (polysaccharide fraction) are not directly translatable to human dosing without pharmacokinetic bridging studies.
Is Agaricus blazei safe to take with chemotherapy?
Agaricus blazei has been used alongside chemotherapy in Japanese observational oncology settings, with some reports of preserved NK cell activity during treatment. However, its immunostimulatory beta-glucans could theoretically interact with immunosuppressive chemotherapy protocols, and no rigorous RCTs have established safety or efficacy in this combination. Patients undergoing cancer treatment should obtain medical clearance before use, as drug interactions with specific chemotherapy agents have not been formally studied.
What is the difference between Agaricus blazei and other medicinal mushrooms like reishi or shiitake?
Agaricus blazei, reishi (Ganoderma lucidum), and shiitake (Lentinula edodes) all contain immunomodulatory beta-glucans but differ in their specific polysaccharide structures and secondary bioactive profiles. AbM is particularly notable for its high ergosterol content (73–90 mg/100g dry powder) with documented antitumor properties and for its unique antifungal compounds — linoleic acid and glycerol monolinoleate — not prominently featured in reishi or shiitake. Reishi is better characterized for its triterpenoid content and adaptogenic properties, while shiitake-derived AHCC (active hexose correlated compound) has more clinical trial data than AbM for human immune outcomes.
Are there any side effects or drug interactions with Agaricus blazei?
Formal adverse event data for Agaricus blazei are limited given the absence of large clinical trials, but theoretical interactions include antagonism with immunosuppressive drugs (cyclosporine, corticosteroids, tacrolimus) due to AbM's T-cell and cytokine-upregulating activity. Its in vitro alpha-glucosidase inhibition raises the possibility of additive blood sugar lowering when combined with antidiabetic medications such as acarbose or insulin, warranting glucose monitoring. Individuals with Agaricaceae mushroom allergies, pregnant or breastfeeding women, and patients on organ transplant immunosuppression should avoid use until more comprehensive safety data are available.
What is the active compound in Agaricus blazei that provides immune support?
The primary active compound in Agaricus blazei is a polysaccharide fraction called AbMP (Agaricus blazei Murrill polysaccharide), which is rich in beta-glucans. These beta-glucans work by increasing production of immune signaling molecules like TNF-α and IL-6, while simultaneously expanding CD4⁺ and CD8⁺ T-cell populations to support both innate and adaptive immune responses. Research shows that immune-modulating effects are most pronounced at doses of 150–200 mg/kg in animal studies, suggesting a dose-dependent mechanism.
How does Agaricus blazei's ergosterol content contribute to its antitumor potential?
Ergosterol, a sterol compound isolated from Agaricus blazei, has demonstrated antitumor activity in murine (mouse) sarcoma models, with tumor suppression ratios increasing in a dose-dependent manner. This compound appears to work through distinct mechanisms from the polysaccharide fraction, offering a complementary approach to the mushroom's overall bioactive profile. While these results are promising in preclinical research, human clinical trials are needed to establish efficacy and optimal dosing for cancer support applications.
What makes Agaricus blazei extract more effective than whole mushroom powder?
Agaricus blazei extracts concentrate beta-glucan polysaccharides and ergosterol at higher levels than whole mushroom powder, potentially allowing for lower doses to achieve equivalent immune-modulating effects. The extraction process removes indigestible chitin and other non-bioactive components, improving bioavailability of the active compounds responsible for TNF-α and IL-6 stimulation. Standardized extracts typically provide controlled levels of AbMP polysaccharides, making them more consistent for supplementation compared to variable whole mushroom preparations.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w agaricus-blazei-agaricus-blazei-murrill curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
